Moderna announced two supply agreements for the Covid-19 Vaccine Moderna: one with the government of Taiwan for 5 million doses and another with the government of Colombia for 10 million doses.
Under the terms of the agreements, deliveries would begin in mid-2021. The Covid-19 Vaccine Moderna is not currently approved for use in Taiwan or Colombia, and the company will work with regulators to pursue necessary approvals prior to distribution.
“We thank the governments of both Taiwan and Colombia for partnering with us to bring the Covid-19 Vaccine Moderna to Taiwan and Colombia. Both governments have moved quickly to get this done in the face of the pandemic and we appreciate their collaboration,” said Stéphane Bancel, chief executive officer of Moderna.
The Covid-19 Vaccine Moderna (referred to in the US as the Moderna Covid-19 Vaccine) is an mRNA vaccine against Covid-19 encoding for a prefusion stabilized form of the Spike (S) protein, which was co-developed by Moderna and investigators from the National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Center. The first clinical batch, which was funded by the Coalition for Epidemic Preparedness Innovations, was completed on February 7, 2020 and underwent analytical testing; it was shipped to the National Institutes of Health (NIH) on February 24, 42 days from sequence selection.
